KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesLong-Term Debt RepaymentsNet Cash FlowNet IncomeOther Working Capital ChangesOther financing activitiesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Esperion Therapeutics (ESPR) Shares Issued (2018 - 2025)

Esperion Therapeutics (ESPR) has disclosed Shares Issued for 8 consecutive years, with $72.6 million as the latest value for Q4 2025.

  • For the quarter ending Q4 2025, Shares Issued rose 195.69% year-over-year to $72.6 million, compared with a TTM value of $72.6 million through Dec 2025, up 390.25%, and an annual FY2025 reading of $72.6 million, up 390.25% over the prior year.
  • Shares Issued was $72.6 million for Q4 2025 at Esperion Therapeutics, up from -$75.9 million in the prior quarter.
  • Across five years, Shares Issued topped out at $90.7 million in Q1 2024 and bottomed at -$75.9 million in Q4 2024.
  • Average Shares Issued over 5 years is $13.1 million, with a median of $2.7 million recorded in 2021.
  • Peak annual rise in Shares Issued hit 12873.87% in 2022, while the deepest fall reached 12597.46% in 2022.
  • Year by year, Shares Issued stood at $551000.0 in 2021, then crashed by 12597.46% to -$68.9 million in 2022, then surged by 176.14% to $52.4 million in 2023, then crashed by 244.7% to -$75.9 million in 2024, then soared by 195.69% to $72.6 million in 2025.
  • Business Quant data shows Shares Issued for ESPR at $72.6 million in Q4 2025, -$75.9 million in Q4 2024, and $90.7 million in Q1 2024.